$0.01
(1.98%)
Add to watchlist
Create an alert
Stocks and Shares ISAVYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Company Information
About this company
Key people
David Domzalski
President, Chief Executive Officer, Director
Tyler Zeronda
Chief Financial Officer, Treasurer
Iain Stuart
Chief Scientific Officer
Mutya Fonte Harsch
Chief Legal Officer, General Counsel, Secretary
Patrick G. Lepore
Lead Independent Director
Sharon Barbari
Independent Director
Steven L. Basta
Independent Director
Elisabeth A. Sandoval Little
Independent Director
Click to see more
Key facts
- Shares in issue33.29m
- EPICVYNE
- ISINUS92941V3087
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$18.43m
- Employees13
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.